A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Orally Administered BMS-986485 in Healthy Adult Participants (Part A), and a Conditional Open-label Study to Evaluate the Relative Bioavailability of Alternate Formulations of BMS-986485 in Healthy Adult Participants (Part B)

Inclusion Criteria: * Participants must have body mass index (BMI) range of 18 to 33 kg/m2. Exclusion Criteria: * Participants must not have any significant medical condition (including but, not limited to, neurological, GI, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, or other major disorders). * Participants mut not have any major surgery or planned surgery (except GI surgery) within 12 weeks of study intervention administration. * Participants mut not have history of neurological condition (including stro…